These results demonstrate that upregulated PC-mediated pyruvate anaplerosis in CML LSCs, which is less affected by imatinib than PDH-mediated pyruvate oxidation (Fig. 2l), can be targeted with MSDC-0160. This evidence concerns the gene PDP1 and chronic myelogenous leukemia, BCR-ABL1 positive.